PVCT
What one share of Provectus Biopharmaceuticals holds
Pharmaceutical Preparations
Provectus Biopharmaceuticals’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$0.01 |
|---|---|
| Cash and investments | $0.00 |
| Debt | $0.00 |
| Book value | −$0.01 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | — | −$0.12 | — | −$0.09 | — | $0.01 |
| 2017 | — | −$0.04 | $0.00 | −$0.03 | — | −$0.03 |
| 2018 | — | −$0.02 | — | −$0.01 | — | −$0.05 |
| 2019 | — | −$0.02 | — | −$0.02 | — | −$0.06 |
| 2020 | — | −$0.02 | — | −$0.01 | — | −$0.08 |
| 2021 | — | −$0.01 | — | −$0.00 | — | −$0.01 |
| 2022 | $0.00 | −$0.01 | — | −$0.01 | — | −$0.01 |
| 2023 | $0.00 | −$0.01 | — | −$0.01 | — | −$0.02 |
| 2024 | $0.00 | −$0.01 | — | −$0.01 | — | −$0.01 |
| 2025 | $0.00 | −$0.01 | — | −$0.01 | — | −$0.01 |